Xenetic Biosciences is trading 10% down at $1.89, with no clear company-specific catalyst identified. - The company announced that the first patient was dosed on October 15, 2026, in a partner-sponsored DNase and CAR T-cell study for large B-cell lymphoma. - The announcement was positive, and available reporting does not identify it as the cause of the decline. - The supplied biotech-sector trend is positive and does not explain the move.